Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study.

Introduction: To provide real-world insights into migraine patient population in Germany treated with erenumab, focusing on the prescription patterns and reasons for the initial dosage choice.

Methods: SPECTRE was an observational, non-interventional, multicenter, open-label, single-arm study in patients treated with erenumab according to approved local dose and guidelines. The study enrolled adult patients (n = 571; Germany: 105 sites) with migraine who had received erenumab for not more than 3 months before the start of the study.

Cross-reactivity of triptans and sulfonamide antibiotics - a clinically relevant question?

After repeated inquiries from patients whether sulfonamide antibiotic allergy should be considered in the context of taking a triptan, we present here the pharmaceutical background, the chemical structure of triptans, and the clinical relevance in a narrative review. In fact, evidence-based cross-reactivity referring to the well-known allergic reaction of sulfonamide antibiotics has not been described so far.

Household income is associated with attack frequency, but not with the prevalence of headache: an analysis of self-reported headache in the general population in Germany.

Background: Headache disorders are among the most prevalent neurological disorders worldwide. However, whether groups differing in socioeconomic position (SEP) are disproportionately affected by headache disorders has not yet been adequately clarified. Our aim was to analyse (1) the headache prevalence by socioeconomic position (SEP) and (2) the attack frequency by SEP in a German population-based adult sample.